Management ChangeJun 22, 2026, 04:06 PM
Tango Therapeutics Appoints Robert Azelby to Board of Directors
AI Summary
Tango Therapeutics, a clinical-stage biotechnology company, announced the appointment of Robert Azelby to its Board of Directors. Mr. Azelby brings over three decades of biopharmaceutical industry leadership, including deep expertise in oncology commercialization and corporate strategy. His appointment is expected to be invaluable as Tango advances vopimetostat, its investigational PRMT5 inhibitor, towards potential late-stage development for pancreatic cancer.
Key Highlights
- Tango Therapeutics appointed Robert Azelby to its Board of Directors.
- Mr. Azelby brings over three decades of biopharmaceutical leadership experience.
- His expertise includes oncology commercialization, corporate strategy, and board governance.
- Tango is advancing vopimetostat, a PRMT5 inhibitor, towards late-stage development.
- Mr. Azelby previously served as CEO of Eliem Therapeutics and Alder BioPharmaceuticals.
- He held senior commercial leadership roles at Amgen, overseeing a $6 billion oncology portfolio.
- He currently serves on the Boards of ADC Therapeutics, Autolus Therapeutics, and Cardinal Health, Inc.
Price Impact
More from TNGX